𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Treatment of chronic myeloid leukaemia lessons and challenges

✍ Scribed by John M. Goldman

Publisher
Carden Jennings Publishing
Year
2002
Tongue
English
Weight
668 KB
Volume
76
Category
Article
ISSN
0925-5710

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Therapeutic targets in chronic myeloid l
Therapeutic targets in chronic myeloid leukaemia
✍ Nicholas B. Heaney; Tessa L. Holyoake πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 162 KB

## Abstract Chronic myeloid leukaemia (CML) is a clonal disorder of the haemopoietic stem cell arising as a consequence of the formation of the __bcr‐abl__ oncogene. The particular molecular basis of this condition has enabled the development of therapies that selectively target diseased cells. The

Oral idarubicin in the treatment of acut
Oral idarubicin in the treatment of acute myelogenous leukaemia and the blast phase of chronic myeloid leukaemia
✍ S. T. A. Malik; J. Tucker; A. Z. S. Rohatiner; W. Brace; T. A. Lister πŸ“‚ Article πŸ“… 1989 πŸ› John Wiley and Sons 🌐 English βš– 307 KB

Fourteen patients with poor-risk acute myelogenous leukaemia (AML) and five patients with accelerated phase/blast crisis chronic myeloid leukaemia (CML) were treated with 3 days of oral idarubicin (25 mg/m2/ day). No complete remissions or return to chronic phase CML were observed. A fall in the per

Mitoxantrone treatment of murine myeloid
Mitoxantrone treatment of murine myeloid leukaemia sublines
✍ Aminu A. Abubakar; Andrew C. Riches πŸ“‚ Article πŸ“… 1995 πŸ› John Wiley and Sons 🌐 French βš– 569 KB

The low-cell-dose (LD) and the high-cell-dose (HD) transplant variants of the SA7 murine rnyeloid leukaemia cell line have different growth characteristics and clinical presentations. In addition, the low-cell-dose transplant subline (SA7LD) was more responsive than the high-cell-dose variant (SA7HD